Search global stocks & ETFs...Ctrl K
Learn Mode
EW
Stock Profile
10-28
Recommended Metric
Score Card
Explore Scores Tab
3.60
Good
Valuation Score
Key Score
5.00
Very Good
Management
4.00
Good
Growth
5.00
Very Good
Profitability
5.00
Very Good
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending Jun 28, 2027
Current
$86.17
Baseline
High
$115.50
▲
34.04%
Avg
$97.94
▲
13.65%
Low
$85.85
▼
-0.37%
Analyst Ratings based on 42 Analysts
Strong Buy
1229%
Buy
1843%
Hold
1229%
Sell
000%
Strong Sell
000%
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.Read More